| 20.18 -0.26 (-1.27%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.46 | 1-year : | 29.74 |
| Resists | First : | 21.79 | Second : | 25.46 |
| Pivot price | 17.84  |
|||
| Supports | First : | 17.24 | Second : | 14.43 |
| MAs | MA(5) : | 20.14 |
MA(20) : | 17.46 |
| MA(100) : | 29.77 |
MA(250) : | 29.08 |
|
| MACD | MACD : | -0.3 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 84.1 |
D(3) : | 86.9 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 50.4 | Low : | 14.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LENZ ] has closed below upper band by 20.2%. Bollinger Bands are 27.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.5 - 20.61 | 20.61 - 20.71 |
| Low: | 19 - 19.13 | 19.13 - 19.24 |
| Close: | 19.97 - 20.18 | 20.18 - 20.36 |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Mon, 26 Jan 2026
Sovran Advisors LLC Has $4.98 Million Stock Holdings in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Wed, 21 Jan 2026
LENZ Therapeutics and Sarah Jessica Parker Launch ‘Make it VIZZable’ Campaign - VisionMonday.com
Mon, 12 Jan 2026
A Look At LENZ Therapeutics (LENZ) Valuation After VIZZ Launch Momentum And New Lunatus Agreement - Yahoo Finance
Thu, 08 Jan 2026
Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long - Yahoo Finance
Wed, 07 Jan 2026
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - LENZ Therapeutics
Fri, 02 Jan 2026
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year Low - What's Next? - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 98.6 (%) |
| Shares Short | 7,690 (K) |
| Shares Short P.Month | 7,960 (K) |
| EPS | -2.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.78 |
| Profit Margin | 0 % |
| Operating Margin | -151.2 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -28.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.55 |
| Sales Per Share | 0.55 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -9.8 |
| PEG Ratio | 0 |
| Price to Book value | 2.97 |
| Price to Sales | 36.08 |
| Price to Cash Flow | -13.97 |
| Dividend | 7.21 |
| Forward Dividend | 0 |
| Dividend Yield | 35.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|